X0306 4 2019-04-01 0 0001357874 PRECISION BIOSCIENCES INC DTIL 0001397607 Schinazi Raymond F C/O PRECISION BIOSCIENCES, INC. 302 E. PETTIGREW STREET, SUITE A-100 DURHAM NC 27701 1 0 0 0 Common Stock 2019-04-01 4 C 0 36946 13.60 A 36946 I By RFS Partners, LP Common Stock 2019-04-01 4 C 0 56102 A 93048 I By RFS Partners, LP Convertible Promissory Note 13.60 2019-04-01 4 C 0 502466.00 D Common Stock 36946 0 I By RFS Partners, LP Series B Preferred Stock 2019-04-01 4 C 0 119761 D Common Stock 56102 0 I By RFS Partners, LP The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO. /s/ Abid Ansari, Attorney-in-Fact for Raymond F. Schinazi 2019-04-02